Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
German drugmaker Bayer has generally preferred in-licensing deals and other collaborations to multi-billion dollar acquisitions, so executives must have been highly impressed by what they saw of Asklepios BioPharmaceutical (AskBio) to spend $2 billion upfront on buying the US biotech, along with up to $2 billion more depending on certain milestones. 23 November 2020
Biotechnology
US biotech major Amgen has returned all development and commercialization rights for omecamtiv mecarbil and AMG 594 to Cytokinetics. 23 November 2020
Biotechnology
Sanofi has picked up European approval for its four-strain meningococcal disease vaccine MenQuadfi. 23 November 2020
Biotechnology
UK-based rare diseases specialist Mereo BioPharma today announced the appointment of Dr Suba Krishnan as senior vice president of clinical development, effective December 7, 2020. 23 November 2020
Biotechnology
Safe and effective vaccines for the novel coronavirus seem to be like buses: after a long, anxious period of waiting, finally three come along at once. 23 November 2020
Biotechnology
Privately-held UK-based T cell receptor (TCR) specialist Immunocore has announced positive Phase III data from the IMCgp100-202 clinical trial of tebentafusp. 23 November 2020
Biotechnology
The US Food and Drug Administration has approved Zokinvy (lonafarnib) for the treatment of Hutchinson-Gilford Progeria syndrome (HGPS or Progeria) and processing-deficient Progeroid laminopathies (PL). 23 November 2020
Biotechnology
US Biotech Regeneron Pharmaceuticals on Saturday revealed that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the US Food and Drug Administration. 23 November 2020
Biotechnology
Life sciences investment trust Syncona has announced the foundation of a new Syncona company, Purespring Therapeutics, with a £45.0 million ($59.5 million) Series A financing. 21 November 2020
Biotechnology
The US Food and Drug Administration has accepted the Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and granted priority review status. 20 November 2020
Biotechnology
Celgene-backed Chinese biotech Antengene had an initial public offering (IPO) in Hong Kong’s HKEX today (November 20). The Shanghai-based clinical -stage biotech, which develops small molecules and antibodies, raised HK$ 2.63 billion ($400 million) to speed up its further development. 20 November 2020
Biotechnology
Australian CAR-T cell specialist Carina Biotech has inked a deal with Bionomics Limited to create cell therapies using the latter’s first-in-class humanized antibody BNC101. 20 November 2020
Biotechnology
US pharma giant Pfizer and BioNTech have wasted no time following the announcement of positive preliminary Phase III data on their COVID-19. 20 November 2020
Biotechnology
Accelerating the development and commercialization of their anti-inflammatory stem-cell therapy, Australia’s Mesoblast today announced an exclusive worldwide license and collaboration agreement with Swiss pharma giant Novartis. 20 November 2020
Biotechnology
US pharma major Eli Lilly and Incyte on Thursday revealed that the US Food and Drug Administration has issued an Emergency Use Authorization (EUA) for the distribution and emergency use of JAK inhibitor Olumiant (baricitinib) to be used in combination with remdesivir in hospitalized adult and pediatric patients two years of age or older with suspected or laboratory confirmed COVID-19. 20 November 2020
Biotechnology
The China National Medical Products Administration (NMPA) has granted another approval to Chinese biotech BeiGene for Xgeva (denosumab). 20 November 2020
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending Braftovi (encorafenib) plus cetuximab, within its marketing authorization, as an option for treating BRAFV600E mutation-positive metastatic colorectal cancer (mCRC), in adults who have had previous systemic treatment. 20 November 2020
Biotechnology
Clinical-stage Austrian biopharmaceutical company F4 Pharma developing FX06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, announces today the inclusion of the first patient with severe COVID-19 in a study named FX-COVID. 19 November 2020
Biotechnology
Dutch biotech uniQure saw its shares gain 7.7% to $46.04 today, as it announced positive top-line data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B. 19 November 2020
Biotechnology
RNAi therapeutics company Alnylam Pharmaceuticals has announced that the European Commission (EC) has granted marketing authorization for Oxlumo (lumasiran), its treatment of primary hyperoxaluria type 1 (PH1) in all age groups. 19 November 2020
All news
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze